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Abstract: Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic 
strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient dis-
ruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, in-
trinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional che-
motherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for 
treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by 
sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence 
suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional 
chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miR-
NAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anti-
cancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based 
therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic 
strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we pre-
sent an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberra-
tions in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets. 
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1. INTRODUCTION 
 Lung cancer is the first cause of cancer deaths world-
wide, among both men and women [1]. Approximately 80% 
to 90% of people with lung cancer have non-small-cell lung 
cancer (NSCLC), including adenocarcinoma, squamous cell 
carcinoma, large cell carcinoma, and several other types that 
occur rarely [2]. Despite recent advances in surgerical proce-
dures, radiotherapy, chemotherapy and the advent of targeted 
therapies, NSCLC have an overall 5-year survival rate of 
about 16% and high incidence of recurrence [1]. The expla-
nation for this poor prognosis is attributable to the high per-
centage of patients diagnosed with advanced-stage disease 
but also to the primary/secondary resistance to current treat-
ments. Although different mechanisms are associated with 
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chemoresistance and several studies have been performed, 
today, we are still far from fully understanding how to pre-
vent or overcome drug resistance. Hence, we need to expand 
the knowledge on the molecular mechanisms of chemoresis-
tance and drug toxicity, in order to increase the effectiveness 
of current therapeutic strategies or alternatively to create new 
approaches which can improve the life expectancy of pa-
tients affected by lung cancer. 
 Tumors can be intrinsically insensitive to therapeutic 
agents prior to therapy, or resistance may be acquired after 
treatment by tumors that are initially sensitive [3] 
http://www.ncbi.nlm.nih.gov/pubmed/22912349. Until to-
day, various mechanisms, responsible for the drug resistance, 
have been proposed, including increased drug efflux, drug 
metabolism/inactivation, drug target alterations, DNA repair, 
or apoptosis deficiency [4-6]. Frequently, drug resistance can 
be related to higher expression levels of ATP binding cas-
sette (ABC) transporter proteins, such as P-glycoprotein 
(Pgp). Overexpression of ABC transporters can decrease 
intracellular accumulation, thereby conferring resistance to 
drug. This phenomenon, which alters the response to differ-
1873-4316/14 $58.00+.00 © 2014 Bentham Science Publishers  
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ent therapeutic agents, is called "multi-drug resistance" 
(MDR) [7]. Although drug efflux is the main mechanism 
correlated to drug resistance, the altered expression of en-
zymes which cause drug inactivation can decrease the 
amount of free drug available to bind its cellular target [8]. 
In addition, the mutational status of drug targets plays a piv-
otal role in the effectiveness of the therapeutic treatment. For 
example, it has been reported that thymidylate synthase (TS) 
gene amplification, a pemetrexed target, is associated with 
resistance to this drug [9]. Furthermore, approximately 70% 
of patients resistant to gefitinib and erlotinib, EGFR tyrosine 
kinase inhibitors (TKIs), have the secondary EGFR T790M 
mutation or the amplification of c-Met [10]. In some cases, 
drug resistance in tumors, including NSCLC, may be due to 
defects in DNA-repair pathways, such as nucleotide exci-
sion–repair (NER) [11, 12], mismatch-repair (MMR) [13], 
base excision–repair (BER) [14], non-homologous end-
joining (NHEJ) [15] and homologous-recombination (HR) 
[16]. Moreover, it is important to emphasize that the loss of 
intracellular death mechanisms, including apoptotic path-
ways, causes tumor cell survival and cancer progression by 
making the cells resistant to therapeutic agents [17]. 
 In recent years, scientific research has focused on genetic 
and epigenetic alterations responsible for drug resistance. In 
particular, it has been reported that mutations, translocations, 
amplifications, deletions, DNA hypermethylation and his-
tone post-translational modifications may have a key role in 
drug resistance [18]. Recently, several evidence showed that 
microRNAs (miRNAs) are also capable of modulating sensi-
tivity/resistance to conventional or targeted anticancer drugs 
and, for this reason, miRNA-based gene therapy could pro-
vide an innovative anti-cancer strategy. 
2. MiRNA FUNCTION AND BIOGENESIS 
 MiRNAs are a class of small non-coding RNA mole-
cules, approximately 20-25 nucleotides in length, evolution-
arily conserved, encoded by cell endogenous genes [19]. 
MiRNAs negatively regulate gene expression via transla-
tional repression or mRNA degradation, through base pairing 
to a partially complementary site, mostly in the 3’ untrans-
lated region (UTR), of the target messenger RNAs (mRNAs) 
[20]. Since the discovery of miRNAs in the early 1990s, in 
Caenorhabditis elegans, thousands of miRNAs have been 
identified and more than 1000 miRNAs have been detected 
in humans [21]. miRNAs are involved in the regulation of a 
many biological processes, such mechanisms of embryonic 
development, cell differentiation, apoptosis, cell growth con-
trol and metabolic processes. Indeed, recent bioinformatic 
and experimental evidence have estimated that about 30% of 
human genes undergoes miRNA-mediated regulation [22]. 
Given that they control the regulation of crucial biological 
functions, it is easy to understand that miRNAs are also in-
volved in different pathological conditions, such as cancer 
[22]. Moreover, a single miRNA may regulate the expression 
of a large number of genes, and a single mRNA can be target 
of multiple miRNAs [23]. 
 miRNA biogenesis is the multistep process of creating a 
mature and functional miRNA from a miRNA gene. These 
genes are located in introns or exons of a protein-coding 
gene or in the intergenic regions. It is known that their tran-
scription is performed by RNA polymerase II or RNA po-
lymerase III which transcribe for a long primary transcript 
called pri-miRNA, an inactive form of about 1 Kb in length 
[24, 25]. The pri-miRNA is then processed by the micro-
processor complex consisting of Drosha, an RNase III endo-
nuclease, its partner DGCR8 and associated proteins, into an 
approximately 70-90-nucleotide incomplete, hairpin-like, 
miRNA precursor (pre-miRNA) [26]. Pre-miRNAs are ex-
ported from the nucleus into the cytoplasm by Exportin-5. 
Once in the cytosol, pre-miRNAs are then cleaved by Dicer, 
an RNase III endonuclease, to generate a 19- to 23-
nucleotide RNA duplex. This double strand RNA binds the 
protein Argonaute and it is incorporated in the protein com-
plex termed RNA-induced silencing complex (RISC). One of 
the two filaments (filament guide) remains with Argonaute 
and constitutes the mature miRNA, while the other strand 
(passenger strand) is degraded. At this point, the mature 
miRNA may negatively regulate one or more mRNA targets 
by binding to specific sequences at the 3' UTR [27]. MiR-
NAs regulate gene expression through two different mecha-
nisms depending on the complementarity between the 
miRNA and its target site. When there is perfect complemen-
tarity, miRNA determines the mRNA degradation, whereas it 
causes arrest of the translation when the complementarity is 
partial [20, 27] (Fig. 1). 
3. MiRNAS AND CANCER 
 During biogenesis miRNAs are subject to intense tran-
scriptional and post-transcriptional regulation. MiRNA ex-
pression is regulated by different mechanisms such as spe-
cific translational regulation, histone deacetylation and 
methylation, DNA copy alteration and gene mutations affect-
ing proteins regulating miRNA maturation [22, 28]. Moreo-
ver, a significant number of miRNA genes are located close 
to fragile sites of chromosomes and in genomic regions 
which are more prone to amplification, deletion or amuta-
tions and which may interfere with miRNA function [22]. 
Therefore, alterations of miRNA expression have been de-
scribed in several pathological conditions and many miRNAs 
have been associated with the development of different can-
cers but also with biological aggressiveness, metastatic ca-
pacity and resistance to antitumor treatments. The impact of 
miRNAs in cancer was firstly evaluated in leukaemia, where 
miRNA genes were found to be specifically deleted [29]. 
Since then, several studies carried out in order to investigate 
the involvement of miRNAs in various cancers, including 
NSCLC. MiRNAs involved in tumorigenesis may have two 
different roles. MiRNA oncogenes, called oncomirs, promote 
tumor development through the negative regulation of tumor 
suppressor genes. Alternatively, tumor suppressor mi-
croRNA, called anti-oncomiRs, are able to inhibit tumor 
growth by targeting oncogenes [30]. For these reasons, on-
comiRs are up-regulated in cancer cells while anti-oncomiRs 
are down-regulated. For example, miR-21 is overexpressed 
in various cancers, including NSCLC, and acts as oncomiR 
by targeting genes related to proliferation, cell death, and 
invasion such as Apaf1, Faslg and RhoB, that are involved in 
the intrinsic/extrinsic apoptotic pathways [31]. Conversely, 
another study reported that let-7, an anti-oncomiR, has low 
expression in lung cancer compared to normal lung tissue, 
and that let-7 expression is inversely correlated with RAS 
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expression in lung cancer samples [32]. Furthermore, it has 
been reported that miRNA expression is associated with sur-
vival in lung cancer. Yanaihara and collaborators identified 
43 differentially expressed miRNAs between lung cancer 
tissues and adjacent normal tissues and they showed that 
elevated miR-155 and low let7a-2 expression were correlated 
to shorter survival [33]. Subsequently, Yu et al. described a 
5-miRNA signature correlated with disease free survival in 
112 NSCLC patients [34]. 
4. MiRNAS AND DRUG RESISTANCE 
 Drug resistance represents a substantial obstacle in can-
cer treatment by reducing the efficacy both of conventional 
chemotherapeutic drugs and novel targeted agents [35]. In-
creasing evidence suggests that drug-induced dysregulation 
of miRNA function might be involved in the acquisition of 
chemoresistance by modulating the sensitivity of cancer cells 
to anticancer drugs [18, 36, 37]. However, the mechanisms 
by which miRNAs affect drug sensitivity or resistance of 
tumor cells are not yet fully elucidated. Thus, MiRNA ex-
pression profile analysis could be useful to predict and im-
prove drug activity, developing new individualized therapies 
[38]. The up- or down-regulation of miRNAs affects the ex-
pression of several target proteins involved in drug response, 
determining changes in drug sensitivity through different 
molecular mechanisms. These proteins could be drug targets, 
transporters, or components related to cell cycle and apopto-
sis or other key cellular signaling pathways. Hence, the new 
approaches to predict the drug response should integrate the 
miRNA and mRNA expression profiles, considering several 
potential molecular biomarkers. Further studies should aim 
to identify specific miRNA signatures related to drug resis-
tance, by comparing the miRNA expression patterns of sen-
sitive and resistant cells. 
 Furthermore, targeting miRNAs is an emerging field for 
optimization of anti-cancer treatments in order to inhibit tu-
mor cell proliferation and to increase the sensitivity to che-
motherapy [39]. MiRNA expression may be regulated not 
only by targeting specific miRNAs to restore drug sensitiv-
ity, but also by activation of tumor suppressor miRNAs and 
inactivation of oncogenic miRNAs. Since aberrant expres-
sion of miRNAs is involved in the development of chemore-
sistance, correcting these deregulations may provide a thera-
peutic benefit. Several reports have shown that antisense 
oligonucleotides, called anti-miRNAs (anti-miRs) or miRNA 
antagonists (antagomiRs), can block the function of miRNAs 
[40, 41]. Interestingly, in vivo experimental studies showed 
that use of anti-RNAs against specific oncogenic miRNAs 
induced a significant decrease in their expression levels in 
different tissues, resulting in upregulation of related target 
genes [42]. Therefore, targeting selected miRNAs could be 
an innovative therapeutic strategy for anti-cancer therapy in 
order to abolish drug resistance of cancer cells or eliminate 
cells that are usually resistant to conventional therapies, in-
cluding cancer stem cells (CSCs) [43-47]. Another mecha-
nism by which miRNAs can modulate the drug sensitivity 
involves the restoration in expression levels of tumor sup-
pressor miRNAs with miRNA mimics [22]. For example, the 
in vitro transfection of lung cancer cells with let-7 pre-miR 
induced upregulation of let-7 tumor suppressor miRNA and 
 
 
Fig. (1). Schematic overview of the microRNA biogenesis pathway. MicroRNAs biogenesis is a coordinated process regulated by different 
groups of enzymes and associated proteins in the nucleus and cytoplasm. 
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the inhibition of cell proliferation [48]. To date, several stud-
ies have shown that miRNA mimics and anti-miRNAs may 
be useful to restore physiological gene networks in different 
cancer cells and in vivo models, suggesting a new potential 
role in anti-cancer therapy [49]. However, use of synthetic 
oligonucleotides shows some limitations due to their rapid 
degradation and lack of suitable in vivo delivery systems. 
These limitations can be overcome by use of natural agents, 
including curcumin, epigallocatechin-3-gallate (EGCG), isofla-
vone, indole-3-carbinol (I3C) and 3,3’-diinodolylmethane 
(DIM) [50, 51]. For example, the I3C natural agent modu-
lates miR-21 in A549 NSCLC cells, by reducing the expres-
sion levels of this miRNA and increasing the expression of 
miR-21 target proteins, such as PDCD4, PTEN, and RECK 
[52]. Similar studies revealed that natural chemopreventive 
agents that showed no human toxicity might regulate 
miRNA expression, suggesting that their combination with 
chemotherapy could be a new therapeutic approach [53, 54]. 
To date, there are not reports on clinical trials that exploit the 
miRNA approach in order to modulate drug sensitivity for 
cancer therapy. However, several phase II clinical trials are 
ongoing to analyze miRNA expression profiles in patients 
treated with several chemotherapy regimens, including do-
cetaxel, carboplatin, cisplatin, paclitaxel, erlotinib, and 
cetuximab, which are the most used chemotherapeutic agents 
in clinical trials for NSCLC [54]. 
5. MiRNAS AND RESISTANCE TO CONVENTIONAL 
CHEMOTHERAPY IN NSCLC 
 Conventional chemotherapy represents the primary 
therapeutic strategy for most NSCLC and the poor prognosis 
of NSCLCs is mainly due to the failure of chemotherapeutic 
regimens because of intrinsic or acquired resistance mecha-
nisms [35]. Resistant cancer cells cannot be destroyed by 
chemotherapeutic regimens, resulting in side-effects and 
poor prognosis. Novel biomarkers to select patient groups 
with high risk of therapeutic treatment failure are warranted. 
Therefore, in the present review we describe several specific 
miRNAs, which have been associated with drug resistance in 
NSCLC by controlling different signaling pathways, includ-
ing cell cycle, survival, cell proliferation, apoptosis and 
DNA damage repair (Table 1).  
5.1. MiRNAs Involved in Chemoresistance through Cell 
Apoptosis Regulation 
 Cell apoptosis is a complex process that may be achieved 
through the death-receptor or the mitochondria pathways 
[55, 56]. Most antitumor drugs such as antimetabolites, and 
alkylating agents inhibit cancer proliferation by promoting 
cell apoptosis or cell cycle arrest. A decreased susceptibility 
to drug-induced apoptosis causes the development of a drug-
resistant phenotype in several cancer cells [57]. Frequently, 
apoptosis inhibition is induced by upregulation of anti-
apoptotic proteins, such as BCL2, BCL-XL, XIAPs, MET, 
PED/PEA-15 (PED), and tumor suppressors, such as p53, 
PTEN, APC, and by lower expression of pro-apoptotic pro-
teins, such as BAX, BAD, BID, NOXA [58, 59]. Expression 
variations of these molecules are affected by the miRNA 
dysregulation. In recent years research performed on differ-
ent types of cancer, allowed to identify a set of miRNAs cor-
related with drug sensitivity and involved in cell apoptosis 
regulation, including let-7a, miR-15b/16, miR-27a, miR-34, 
miR-130a, miR-199, miR-214, miR-221/222, miR-337 and 
miR-451 [58, 60, 61]. Since a single miRNA can control the 
sensitivity to a wide number of anticancer drugs, miRNAs 
could exert their protective function through survival path-
ways that inhibit downstream activity of many anticancer 
compounds.  
 Docetaxel and paclitaxel belong to family of taxanes and 
are important microtubule-targeting anticancer agents com-
monly used in the therapy of advanced NSCLC. They inhibit 
microtubule dynamics by preventing the microtubule de-
polymerization, leading to arrest of mitosis in metapahase, 
activation of the spindle assembly checkpoint, and thus in-
ducing apoptosis [62-64]. Chemoresistance remains the most 
important obstacle limiting their clinical applications, and 
deregulation of molecules involved in the apoptosis path-
ways is an important mechanism by which miRNAs cause 
resistance to microtubule-targeting agents. Rui and collabo-
rators reported that the expression of three miRNAs (miR-
200b, miR-194 and miR-212) was significantly down-
regulated, while the expression of three other miRNAs (miR-
192, miR-424 and miR-98) was significantly up-regulated in 
docetaxel-resistant SPC-A1 NSCLC cells, suggesting differ-
ential miRNA expression profiles in docetaxel-resistant and 
sensitive tumors [65]. Subsequently, Feng and collaborators 
showed that miR-200b is the most down-regulated miRNA 
in docetaxel-resistant NSCLC cells and it might act as a tu-
mor suppressor to reverse docetaxel resistance, by targeting 
E2F3, whose function is important for the correct cell cycle 
progression [66]. Others studies showed that miR-192 acts as 
a tumor suppressor by modulating the RB1 gene to inhibit 
cell proliferation and induce apoptosis [67], whereas up-
regulation of miR-135a and miR-34c-5p was correlated with 
resistance to apoptosis induction by paclitaxel. In particular, 
increased expression of miR-135a, both in vivo and in vitro, 
induced down-regulation of its direct target, APC, and in-
creased resistance to paclitaxel [68], while miR-34c-5p-
mediated down-regulation of BMF (Bcl-2-modifying factor) 
together with cMyc contributed to resistance to paclitaxel-
induced apoptosis through TP53 down-regulation in A549 
NSCLC cells, [69]. Furthermore, in human NCI-H1155 
NSCLC cells, that are resistant to paclitaxel, introduction of 
a miR-337–3p mimic re-sensitizes the cells to paclitaxel by 
increasing the ability of the drug to determine G2/M block 
and apoptosis [70]. STAT3 and RAP1A were reported as tar-
gets of miR-337-3p. STAT3 is a transcription factor involved 
in angiogenesis, invasion, tumor cell survival, and drug resis-
tance. Its targets include proteins that control cell survival, 
such as cyclin D1, c-myc, survivin, Bcl-2, and p21cip1 [71]. 
The down-regulation of STAT3 and RAP1A by miR-337-3p 
demonstared that STAT3 and RAP1A influence the effect of 
miR-337-3p on paclitaxel sensitivity [58]. 
 In addition, other miRNAs are involved in resistance to 
apoptosis induced by platinum-derived anticancer agents. An 
in vitro study demonstrated that miR-181a and miR-630 
modulate cell death induced by cisplatin in lung cancer cells 
[72]. In particular, miR-181a and miR-630 control apoptosis 
through the mitochondrial/post-mitochondrial steps of the 
intrinsic pathway, including BAX oligomerization, mito-
chondrial transmembrane potential alteration, and proteolytic 
activation of caspase-3 and caspase-9 [72].  
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Table 1.  MicroRNAs involved in resistance to conventional chemotherapy. 
miRNA Expression Drug Targets References 
miR-200b ↓ Docetaxel E2F3 [65, 66] 
miR-194/212 ↓ Docetaxel Various [65] 
miR-192 ↑ Docetaxel RB1 [65, 67] 
miR-98/424 ↑ Docetaxel Various [65] 
miR-100 ↓ Docetaxel Plk1 [93] 
miR-135a ↑ Paclitaxel APC [68] 
miR-34c-5p ↑ Paclitaxel BMF, cMyc [69] 
miR-337-3p ↓ Paclitaxel, Docetaxel STAT3, RAP1A [58, 70] 
miR-181a ↓ Cisplatin BCL-2, ATG5, MAP kinases [72] 
miR-630 ↑ Cisplatin BAX, etc. [72] 
miR-98/453 ↑ Cisplatin TP53 [73] 
miR-181b/497 ↓ Cisplatin BCL-2 [74, 76] 
miR-451 ↓ Cisplatin BCL-2, AKT [75] 
miR-200bc/429 cluster ↓ Cisplatin BCL-2, XIAP [77] 
miR-21 ↑ Cisplatin PTEN [78] 
miR-138 ↓ Cisplatin ERCC1 [96] 
miR-513a-3p ↓ Cisplatin GSTP1 [97] 
miR-24 ↓ TRAIL XIAP [80] 
miR-221/222 ↑ TRAIL PTEN, TIMP3, p27 [81] 
miR-130a ↓ TRAIL MET [84] 
miR-212 ↓ TRAIL PED [86] 
miR-1 ↓ Doxorubicin MET [85] 
miR-128-2 ↑ Cisplatin, Doxorubicin, 5-FU E2F5 [87] 
miR-330 ↑ Gemcitabine E2F1, dCK [88] 
↑ Up-regulated and ↓ down-regulated microRNAs in chemoresistance.  
 
 Recently, Zhang and collaborators reported that miR-98 
and miR-453 increased resistance to cisplatin by down-
regulating TP53 expression, in A549 cells [73]. Furthermore, 
several reports showed that miR-181b, miR-451, miR-497 
and miR-200bc/429 cluster sensitize the cells to platinum-
induced cell death, by down-regulating the expression of 
BCL-2 anti-apoptotic gene, whose overexpression causes 
drug resistance [74-76]. Overexpression of miR-451 inhib-
ited growth and enhanced the sensitivity of A549 lung ade-
nocarcinoma cells to cisplatin, by inducing apoptosis through 
inhibition of Akt signaling pathway, while increased expres-
sion of miR-200bc/429 cluster reduced BCL-2 and XIAP (X-
linked inhibitor of apoptosis protein) protein expression lev-
els [77]. Finally, Gao and collaborators reported that miR-21 
might predict adjuvant platinum-based chemotherapy re-
sponse in NSCLC patients, because its overexpression in-
duces resistance to platinum in A549 cells, by reducing 
PTEN expression and increasing BCL-2 expression [78]. 
 Apoptosis pathways can also be the primary targets of 
anticancer drugs, such as in the case of the Apo2L/tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL), a member of the TNF family that induces pro-
grammed cell death in a variety of cancers [79]. However, a 
significant proportion of tumors are resistant to TRAIL-
induced apoptosis. A recent study reported that miR-24 di-
rectly down-regulates XIAP expression by targeting its 3’ 
UTR and inducing sensitivity to TRAIL in TRAIL-resistant 
lung cells [80]. Furthermore, Garofalo and collaborators per-
formed a genome-wide expression study of miRNAs in 
NSCLC cell lines with differential TRAIL-sensitivity and 
showed the key role of miR-221 and -222 by regulating 
p27kip1 expression and TRAIL-induced caspase machinery 
[81]. In particular, the expression of miR-110, miR-221, 
miR-222 and miR-125b was up-regulated from 5- to 8-fold 
in TRAIL-resistant cells and down-regulated in TRAIL-
sensitive cells [3]. Ectopic overexpression of miR-110,  
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miR-221 and miR-222 induced resistance in H460 sensitive 
cells, while Calu-1 resistant cells transfected with anti-miR-
221 or anti-miR-222 became sensitive to TRAIL [54]. MiR-
221 and miR-222 promote tumorigenesis and metastasis in 
lung cancer, by down-regulating PTEN and TIMP3. Moreo-
ver, a common genetic aberration detected in lung cancer 
progression is activation of MET oncogene signaling [82] 
and miR-221 and miR-222 expression levels are regulated by 
MET through c-Jun transcription factor and JNK activation 
[83]. Similarly, miR-130a induces TRAIL sensitivity, by 
targeting MET and down-regulating miR-221 and miR-222 
[84]. 
 Finally, Nasser and collaborators reported that ectopic 
expression of miR-1 reduces cell proliferation and enhance 
the induction of apoptosis by doxorubicin in A549 cells, by 
promoting the activation of effector caspases and degrada-
tion of the anti-apoptotic member of BCL-2 family Mcl-1 
[85], whereas another study demonstrated that miR-212 
negatively modulates the expression of a death effector do-
main family member, called PED, which is an anti-apoptotic 
factor regulating cellular sensitivity towards TRAIL [86]. 
 These results, summarized in Table 1, suggest that thera-
peutic intervention, involving the use of microRNAs, should 
not only sensitize tumor cells to drug-induced apoptosis but 
also inhibit survival, proliferation, and metastatic properties 
of lung cancer. 
5.2. MiRNAs Involved in Chemoresistance through Cell 
Cycle Regulation 
 MiRNAs can be associated with cell cycle deregulation 
that might also influence resistance to anticancer agents  
(Table 1). Some miRNAs may modulate the chemoresistance 
by targeting E2F transcription factor family that is involved 
in the regulation of cell cycle. Recently, Donzelli and col-
laborators showed that miR-128-2 expression, induced by a 
mutant p53 protein, inhibits apoptosis and causes increased 
resistance to doxorubicin, cisplatin and 5-fluorouracil in 
NSCLC cells. MiR-128-2, by targeting E2F5, inhibits its 
repressive activity on transcription of p21waf1, which exerts 
an anti-apoptotic effect by reducing pro-caspase-3 cleavage 
[87]. Additionally, miR-330 expression was correlated with 
resistance to gemcitabine in various lung cancer cell lines, 
since gemcitabine-sensitive cells showed a lower expression 
of miR-330 than gemcitabine-resistant cells. E2F1 is an indi-
rect target of miR-330, because miR-330 overexpression 
reduced E2F1-mediated Akt phosphorylation [88]. Moreo-
ver, miR-330 expression was inversely correlated with the 
mRNA expression of deoxycytidine kinase (dCK), support-
ing a role of miR-330 in post-transcriptional regulation of 
dCK, which is critical for phosphorylation of deoxynucleo-
side analogs, such as gemcitabine and cytarabine [89]. MiR-
200b is another miRNA correlated to E2F transcription fac-
tor family. Ectopic miR-200b expression reduced chemore-
sistance to docetaxel by inhibition of cell proliferation, in-
duction of apoptosis, and arrest of cell cycle at G2/M [66]. 
MiR-200b directly targets E2F3, which usually acts as a 
transcriptional activator by increasing cellular proliferation 
through the G1/S transition [90-92].  
 MiR-100 had a significantly lower expression in do-
cetaxel-resistant SPC-A1/DTX cells compared with parental 
SPC-A1 cells. MiR-100 could induce sensitivity to do-
cetaxel, by targeting Plk1 [93], which plays a key role in cell 
cycle progression through various mitosis stages, as directly 
promotes entry in mitosis by activating Cdc25C [94] and 
Cdk1/Cyclin B complex [95]. Furthermore, as reported 
above, overexpression of miR-337-3p confers sensitivity to 
paclitaxel, inducing G2/M arrest [70]. 
5.3. MiRNAs Involved in Chemoresistance through DNA 
Damage Repair Mechanisms 
 Some miRNAs may modulate the chemoresistance 
through regulation of DNA damage repair (DDR) mecha-
nisms (Table 1). For instance, the expression of excision 
repair cross-complementation group 1 (ERCC1) gene, in-
volved in NER, was correlated with resistance to platinum-
derived drugs. In 2011, Wang and collaborators reported the 
aberrations of 14 miRNAs in the A549/DDP cisplatin-
resistant cell lines in comparison with the parental A549 cell 
lines. Among these, miR-138 could affect the development 
of resistance to cisplatin in NSCLC, by negatively regulating 
ERCC1 [96]. Furthermore, glutathione S-transferase P1 
(GSTP1) plays a key role in protecting cells from carcino-
gens and cytotoxic agents. MiR-513a-3p could therefore 
increase apoptosis induced by cisplatin in human NSCLC 
cell lines, by targeting GSTP1 [97]. In addition, miR-630 
recently emerged as a novel modulator of response to cis-
platin, since its overexpression, not only induced cell cycle 
arrest, but also counteract early events of the response to 
DNA damage, such as the phosphorylation of ATM kinase 
and of the ATM substrates histone H2AX and p53 [54], 
which affect response to DNA damage. 
6. MiRNAS AND RESISTANCE TO TARGETED 
THERAPY IN NSCLC 
 Drugs that target the epidermal growth factor receptor 
(EGFR) are now major actors in the treatment of NSCLC. 
These drugs allowed us to better understand the molecular 
biology of NSCLC, including the discovery that activating 
mutations in EGFR correlated to a better response to anti-
EGFR treatments. In fact, a strong association between acti-
vating mutations in the EGFR tyrosine kinase domain and 
the response to the EGFR tyrosine kinase inhibitors (TKIs) 
gefitinib and erlotinib has been demonstrated in many clini-
cal trials. Although EGFR-mutant NSCLCs initially respond 
to anti-EGFR drugs, most of these cancers ultimately be-
come resistant. The main mechanisms of acquired resistance 
to these drugs include secondary mutations in EGFR, such as 
the gatekeeper T790M mutation, detected in approximatively 
50% of resistant cases; and amplification of the MET onco-
gene [98], observed in 5-20% of resistant cases [99]. This 
resistance can be overcome by EGFR inhibition by miR-7, 
which targets three sites in the 3’-untranslated region of 
EGFR mRNA [100]. Recent evidence showed that several 
miRNAs can be involved in resistance to different drugs 
targeting EGFR (Table 2). Preliminary studies in NSCLC 
cell lines demonstrated that increased expression of miR-21, 
miR-23a, miR-23b, and miR-29 are associated with resis-
tance in three sunitinib-resistant variants of H1703 cells 
[101, 102], while decreased miR-424 levels are associated 
with increased resistance to erlotinib and vandetanib [103]. 
Recently, it has been reported that the HCC827/GR, gefitinib
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Table 2. MicroRNAs involved in resistance to novel targeted agents. 
miRNA Expression Drug Targets References 
miR-21/23b ↑ Erlotinib, Vandetanib, Sunitinib TKR [54, 101, 102] 
miR-23a/29 ↑ Sunitinib N/S [101, 102] 
miR-424 ↓ Erlotinib, Vendetanib N/S [103, 108] 
miR-200c ↓ Erlotinib EMT [107] 
miR-214 ↑ Gefitinib PTEN, AKT [104] 
miR-30b/30c ↑ Gefitinib BIM [83] 
miR-221/222 ↑ Gefitinib APAF-1 [83] 
miR-103 ↓ Gefitinib PKC-ε [83] 
miR-203 ↓ Gefitinib SRC [83] 
miR-128b ↓ Gefitinib EGFR [108] 
miR-126 ↑ Gefitinib AKT, ERK [105, 106] 
miR-145 ↓ Gefitinib AKT, ERK, c-Myc [105, 106] 
↑ Up-regulated and ↓ down-regulated microRNAs in drug resistance. N/S = target not specified. 
 
resistant cell line, showed a relevant up-regulation of miR-
214 and the knockdown of miR-214 altered the expression 
levels of PTEN and p-Akt, and re-sensitized HCC827/GR to 
gefitinib [104]. The activation of both p-Akt and ERK can be 
regulated by miR-126, whose overexpression inhibits the cell 
proliferation and significantly enhances the cytotoxicity in-
duced by gefitinib in H460 and A549 cells. In addition, miR-
126 is involved in cell adhesion, migration, invasion, angio-
genesis, and regulation of VEGF-A [105]. Also, miR-145 
down-regulation is associated with resistance to gefitinib, 
whereas its overexpression inhibits the cell proliferation by 
targeting c-Myc [106]. In 2012, Bryant and collaborators 
reported that the expression levels of 13 miRNAs might pre-
dict response to erlotinib in cancer cell lines, and discrimi-
nates primary tumors from metastatic lesions. These miR-
NAs, in particular miR-140-3p, miR-628-5p, miR-518f, 
miR-636, miR-301a, miR-34c, miR-224, miR-197, miR-205, 
miR135b, miR-200b, miR-200c, and miR-141, regulate proteins 
that are potentially involved in epithelial-to-mesenchymal tran-
sition (EMT). Interestingly, treatment with TGFβ1 modu-
lated the expression of these miRNAs and EMT proteins 
and, for this reason, they hypothesized that the tumor micro-
environment elicits TGFβ1 and promotes a miRNA expres-
sion pattern that induces resistance to anti-EGFR and favors 
the induction of EMT, invasion, and metastasis in lung can-
cer cells [107]. A pivotal study reported that miR-30b, miR-
30c, miR-221 and miR-222 are regulated by both EGF and 
MET receptors, while miR-103 and miR-203 are modulated 
only by MET. These miRNAs have important roles in gefit-
inib-induced apoptosis and EMT of NSCLC cells. In fact, 
treatment with gefitinib causes apoptosis through the down-
regulation of miR-30b, miR-30c, miR-221 and miR-222 and 
the consequent overexpression of APAF-1 and BIM in gefit-
inib-sensitive cells. Conversely, gefitinib did not affect miR-
30b, miR-30c, miR-221 and miR-222 expression in gefit-
inib-resistant cells as a result of MET overexpression. Inter-
estingly, gefitinib-resistance was overcome through MET 
inhibitors, which down-regulated these microRNAs and sen-
sitized NSCLCs to gefitinib [83].  
 To date, little is known about the possible correlation of 
miRNAs expression with NSCLC patients outcome after 
treatment with EGFR inhibitors. Weiss and collaborators 
reported that miR-128b is a direct regulator of EGFR and 
loss of heterozygosity of this miRNA is frequently found in 
NSCLC patients, and is positively correlated with clinical 
response and survival after gefitinib treatment [108]. An-
other study by Seike and collaborators reported a significant 
association between the EGFR mutation status and miR-21 
expression, but these results were not validated in a study on 
a larger number of NSCLC tissues [109]. Table 2 summa-
rizes miRNAs involved in resistance to targeted therapy in 
NSCLC. 
7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 Resistance to conventional chemotherapy can be induced 
by several mechanisms which are partially overlapping with 
those involved in resistance to novel targeted agents, includ-
ing drug inactivation, modifications of drug targets, reduced 
drug uptake and increased drug elimination. However, recent 
data showed that drug resistance mechanisms might also be 
regulated by alterations in miRNA expression. Today, sev-
eral in vitro studies are ongoing to investigate molecular 
mechanisms underlying the role of microRNAs in NSCLC 
resistance, in order to exploit miRNAs as therapeutic targets. 
The identification of new possible molecular mechanisms of 
resistance to conventional chemotherapy and novel targeted 
therapies could represent an important tool to select NSCLC 
patients who could have benefit from treatment. This re-
search provides multidisciplinary approaches, by promoting 
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the interaction between basic research and clinical research, 
and integrating significantly the fields of oncology and mo-
lecular biology. 
 In conclusion, recent studies showed that miRNAs may 
play important roles in the regulation of anti-cancer drug 
resistance, by regulating several signaling pathways, includ-
ing apoptosis, cell cycle, proliferation and DNA damage 
repair, as well as the EGFR pathway. Hopefully, in the near 
future, the expression profiles of specific miRNAs could 
provide new information about resistance of individual tu-
mors to different treatments before starting therapy, while 
modulation of the expression of specific miRNAs during 
treatment might offer a new tool for the prediction of ac-
quired resistance. Moreover, specific modulation of miRNA 
activity could improve the activity of conventional chemo-
therapy and novel targeted agents in NSCLC patients. There-
fore, identification of candidate miRNAs affecting drug re-
sistance and analysis of their molecular mechanisms could 
be useful for designing novel and targeted miRNA-based 
therapeutic strategies to improve the clinical outcome of 
NSCLC patients. 
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